Resolution of inflammation: therapeutic potential of pro-resolving lipids in type 2 diabetes mellitus and associated renal complications

The role of inflammation in the pathogenesis of type 2 diabetes mellitus (T2DM) and its associated complications is increasingly recognized. The resolution of inflammation is actively regulated by endogenously produced lipid mediators such as lipoxins, resolvins, protectins, and maresins. Here we review the potential role of these lipid mediators in diabetes-associated pathologies, specifically focusing on adipose inflammation and diabetic kidney disease, i.e., diabetic nephropathy (DN). DN is one of the major complications of T2DM and we propose that pro-resolving lipid mediators may have therapeutic potential in this context. Adipose inflammation is also an important component of T2DM-associated insulin resistance and altered adipokine secretion. Promoting the resolution of adipose inflammation would therefore likely be a beneficial therapeutic approach in T2DM.

• Publication year

  2012

• Venue

  Front. Immun.

• Publication date

  2012-10-18

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.3389/fimmu.2012.00318PMID 23087692PMCID 3474937
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on potential drugs for the treatment of diabetic kidney disease.

  2012cited by this paper
• Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl

  2012cited by this paper
• Aspirin-Triggered Lipoxin A4 Attenuates Lipopolysaccharide-Induced Intracellular ROS in BV2 Microglia Cells by Inhibiting the Function of NADPH Oxidase

  2012cited by this paper
• Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation

  2012cited by this paper
• Lipoxin A4 attenuates adipose inflammation

  2012influential reference
• Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus.

  2012cited by this paper
• Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

  2011cited by this paper
• Macrophages in renal disease.

  2011influential reference
• Lipoxin A 4 Inhibits Porphyromonas gingivalis-Induced Aggregation and Reactive Oxygen Species Production by Modulating Neutrophil-Platelet Interaction and CD 11 b Expression † ‡

  2011influential reference
• Podocytes as target of vitamin D.

  2011cited by this paper
• [Effect of lipoxin A(4) on lipopolysaccharide-induced endothelial hyperpermeability in human umbilical vein endothelial cell].

  2011cited by this paper
• Lipoxin A4 and benzo‐lipoxin A4 attenuate experimental renal fibrosis

  2011influential reference
• Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

  2011influential reference
• Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese‐diabetic mice

  2011influential reference
• Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b–4 CKD

  2011influential reference
• Glycated haemoglobin--a marker and predictor of cardiovascular disease.

  2011cited by this paper
• Macrophages in kidney repair and regeneration.

  2011cited by this paper
• Lipoxin A4 Inhibits Porphyromonas gingivalis-Induced Aggregation and Reactive Oxygen Species Production by Modulating Neutrophil-Platelet Interaction and CD11b Expression

  2011cited by this paper
• Type 2 diabetes as an inflammatory disease

  2011influential reference
• Effect of Lipoxin A4 on Lipopolysaccharide-Induced Endothelial Hyperpermeability

  2011cited by this paper
• Diabetes: Bardoxolone improves kidney function in type 2 diabetes

  2011influential reference
• TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome.

  2011cited by this paper
• Pirfenidone for diabetic nephropathy.

  2011influential reference
• Macrophages and diabetic nephropathy.

  2010cited by this paper
• New pharmacological treatments for improving renal outcomes in diabetes

  2010cited by this paper
• The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans.

  2010cited by this paper
• Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab

  2010cited by this paper
• Recent advances in the chemistry and biology of stable synthetic Lipoxin analogues

  2010cited by this paper
• Adipose tissue macrophages in insulin resistant subjects are 1 associated with collagen VI, fibrosis and demonstrate 2 alternative activation

  2010cited by this paper
• Specialized pro-resolving lipid mediators in the inflammatory response: An update.

  2010cited by this paper
• The Effects of Salsalate on Glycemic Control in Patients With Type 2 Diabetes

  2010cited by this paper
• Resolvin D1 binds human phagocytes with evidence for proresolving receptors

  2010cited by this paper
• Lipoxin A4 Inhibits Transition of Epithelial to Mesenchymal Cells in Proximal Tubules

  2010cited by this paper
• Adipose tissue as an endocrine organ.

  2010cited by this paper
• The Role of Adipose Tissue and Lipotoxicity in the Pathogenesis of Type 2 Diabetes

  2010influential reference
• Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

  2010cited by this paper
• Renoprotective effects of vitamin D analogs.

  2010cited by this paper
• Resolvin E1 Regulates Adenosine Diphosphate Activation of Human Platelets

  2010cited by this paper
• Molecular Circuits of Resolution in Renal Disease

  2010influential reference
• Identification of MicroRNA-93 as a Novel Regulator of Vascular Endothelial Growth Factor in Hyperglycemic Conditions*

  2010cited by this paper
• Resolution of Adipose Tissue Inflammation

  2010cited by this paper
• Lipoxin A 4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells

  2010cited by this paper
• Adipose tissue macrophages in insulin-resistant subjects are associated with collagen VI and fibrosis and demonstrate alternative activation.

  2010cited by this paper
• Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy.

  2009cited by this paper
• Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions

  2009cited by this paper
• Systems approach to inflammation resolution: identification of novel anti‐inflammatory and pro‐resolving mediators

  2009cited by this paper
• Pirfenidone is renoprotective in diabetic kidney disease.

  2009cited by this paper
• Deletion of Tumor Necrosis Factor-α Receptor 1 (TNFR1) Protects against Diet-induced Obesity by Means of Increased Thermogenesis*

  2009cited by this paper
• Resolvins and protectins: mediating solutions to inflammation

  2009influential reference
• Resolution of renal inflammation: a new role for NF-kappaB1 (p50) in inflammatory kidney diseases.

  2009cited by this paper
• Lipoxin A4: Anti-Inflammatory and Anti-Angiogenic Impact on Endothelial Cells1

  2009cited by this paper
• The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study

  2009cited by this paper
• Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs.

  2009cited by this paper
• Lipoxins: resolutionary road

  2009influential reference
• Obesity‐induced insulin resistance and hepatic steatosis are alleviated by ω‐3 fatty acids: a role for resolvins and protectins

  2009cited by this paper
• Lipoxin A4 inhibits IL-1beta-induced IL-8 and ICAM-1 expression in 1321N1 human astrocytoma cells.

  2009cited by this paper
• Vitamin D: a new hope for chronic kidney disease?

  2009cited by this paper
• Inflammation and insulin resistance

  2008cited by this paper
• Macrophage diversity in renal injury and repair.

  2008cited by this paper
• Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.

  2008cited by this paper
• Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets.

  2008cited by this paper
• MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.

  2008cited by this paper
• Design and synthesis of benzo-lipoxin A4 analogs with enhanced stability and potent anti-inflammatory properties.

  2008cited by this paper
• Increased interleukin (IL)-1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation.

  2008cited by this paper
• Anti-inflammatory and proresolving lipid mediators.

  2008influential reference
• MicroRNA‐377 is up‐regulated and can lead to increased fibronectin production in diabetic nephropathy

  2008cited by this paper
• Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

  2007cited by this paper
• Interleukin-1-receptor antagonist in type 2 diabetes mellitus.

  2007cited by this paper
• Salicylate poisoning: An evidence-based consensus guideline for out-of-hospital management

  2007cited by this paper
• MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors

  2007cited by this paper
• Resolvin E1 Selectively Interacts with Leukotriene B4 Receptor BLT1 and ChemR23 to Regulate Inflammation1

  2007influential reference
• Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease.

  2007cited by this paper
• Synthesis and anti-inflammatory effect of lipoxins in human airway epithelial cells.

  2007cited by this paper
• Inflammatory cells in renal injury and repair.

  2007cited by this paper
• Absence of CC Chemokine Ligand 2 Does Not Limit Obesity-Associated Infiltration of Macrophages Into Adipose Tissue

  2007cited by this paper
• Resolvin E1 and protectin D1 activate inflammation-resolution programmes

  2007influential reference
• Resolvin E1 promotes mucosal surface clearance of neutrophils: a new paradigm for inflammatory resolution

  2007cited by this paper
• Obesity induces a phenotypic switch in adipose tissue macrophage polarization.

  2007cited by this paper
• The Lipoxin A4 Receptor Is Coupled to SHP-2 Activation

  2007cited by this paper
• Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways.

  2007cited by this paper
• Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy.

  2007cited by this paper
• Aromatic lipoxin A4 and lipoxin B4 analogues display potent biological activities.

  2007cited by this paper
• Increased Inflammatory Properties of Adipose Tissue Macrophages Recruited During Diet-Induced Obesity

  2007cited by this paper
• Insulin resistance in patients with rheumatoid arthritis: effect of anti‐TNFα therapy

  2007cited by this paper
• Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition.

  2007cited by this paper
• NF-κB1 (p50) Homodimers Differentially Regulate Pro- and Anti-inflammatory Cytokines in Macrophages*

  2006cited by this paper
• Reversible constriction of the fetal ductus arteriosus after maternal use of topical diclofenac and methyl salicylate

  2006cited by this paper
• Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.

  2006cited by this paper
• Aspirin-triggered lipoxin A4 blocks reactive oxygen species generation in endothelial cells: A novel antioxidative mechanism

  2006cited by this paper
• Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent

  2006cited by this paper
• Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice.

  2006cited by this paper
• Diabetes, Inflammation, Proinflammatory Cytokines, and Diabetic Nephropathy

  2006cited by this paper
• Lipoxin A4 inhibits connective tissue growth factor-induced production of chemokines in rat mesangial cells.

  2006cited by this paper
• Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression

  2006influential reference
• Lipoxin A4 inhibits proliferation of human lung fibroblasts induced by connective tissue growth factor.

  2006influential reference
• The Lipoxin Receptor ALX: Potent Ligand-Specific and Stereoselective Actions in Vivo

  2006influential reference
• Resolvin D Series and Protectin D1 Mitigate Acute Kidney Injury1

  2006cited by this paper
• Lipoxin A4 Redistributes Myosin IIA and Cdc42 in Macrophages: Implications for Phagocytosis of Apoptotic Leukocytes1

  2006cited by this paper
• Reduction of Renal Fibrosis as a Result of Liposome Encapsulated Clodronate Induced Macrophage Depletion after Unilateral Ureteral Obstruction in Rats

  2006influential reference
• Host-mediated resolution of inflammation in periodontal diseases.

  2006cited by this paper

• Formylpeptide receptors: A novel target to treat cardiometabolic complications.

  2025cites this paper
• Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy

  2025cites this paper
• Utilization of lipoxins and other specialised pro-resolving mediators in the prevention and treatment of diabetic nephropathy and diabetic cardiovascular disease

  2024cites this paper
• Association of adipose tissue mediators with the development of cancer in patients with metabolic syndrome

  2024cites this paper
• Immunology of chronic low-grade inflammation: relationship with metabolic function.

  2023cites this paper
• Cardiovascular/Stroke Risk Stratification in Diabetic Foot Infection Patients Using Deep Learning-Based Artificial Intelligence: An Investigative Study

  2022cites this paper
• Impaired brown adipose tissue is differentially modulated in insulin-resistant obese wistar and type 2 diabetic Goto-Kakizaki rats.

  2021cites this paper
• Lipoxins and synthetic lipoxin mimetics: therapeutic potential in renal diseases.

  2021cites this paper
• Actions of annatto-extracted tocotrienol supplementation on obese postmenopausal women: study protocol for a double-blinded, placebo-controlled, randomised trial

  2020cites this paper
• Therapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease.

  2020cites this paper
• The prospective curative role of lipoxin A4 in induced gastric ulcer in rats: Possible involvement of mitochondrial dynamics signaling pathway

  2020cites this paper
• Mesenchymal Stem Cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by Targeting Transforming Growth Factor β (TGF-β)/smad Pathway and Pro-Inflammatory Cytokines

  2019cites this paper
• Asymmetric synthesis and biological evaluation of imidazole- and oxazole-containing synthetic lipoxin A4 mimetics (sLXms).

  2019cites this paper
• Anti‐inflammatory effects of resolvins in diabetic nephropathy: Mechanistic pathways

  2019cites this paper
• The effect of western diet on mice brain lipid composition

  2019cites this paper
• Proresolving protein Annexin A1: The role in type 2 diabetes mellitus and obesity.

  2018cites this paper
• Lipoxins Protect Against Inflammation in Diabetes-Associated Atherosclerosis

  2018cites this paper
• Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients.

  2017cites this paper
• Adipocyte lipid storage and adipokine production are modulated by lipoxygenase-derived oxylipins generated from 18-carbon fatty acids.

  2017cites this paper
• Exploration of the perceived and actual benefits of omega-3 fatty acids and the impact of FADS1 and FADS2 genetic information on dietary intake and blood levels of EPA and DHA.

  2017cites this paper
• Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.

  2017cites this paper
• Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms

  2017cites this paper
• Maresin 1 Mitigates High Glucose-Induced Mouse Glomerular Mesangial Cell Injury by Inhibiting Inflammation and Fibrosis

  2017cites this paper
• MiR-30a targets IL-1α and regulates islet functions as an inflammation buffer and response factor

  2017cites this paper
• New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration.

  2017cites this paper
• Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.

  2016cites this paper
• Therapeutic Targets for Management of Periodontitis and Diabetes

  2016cites this paper
• The role of lipoxins in cardiometabolic physiology and disease

  2016cites this paper
• Extracted Triterpenes from Antrodia cinnamomea Reduce the Inflammation to Promote the Wound Healing via the STZ Inducing Hyperglycemia-Diabetes Mice Model

  2016cites this paper
• Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood

  2016cites this paper
• anti-inflammatory nutrients obesity-associated metabolic-inflammation from childhood through to adulthood.

  2016cites this paper
• Lipoxins and aspirin-triggered lipoxins in resolution of inflammation.

  2015cites this paper
• Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.

  2015influential citation
• Specialised lipid mediators and their targets.

  2015cites this paper
• Effects of platycodins on liver complications of type 2 diabetes.

  2014cites this paper
• Association of red blood cell n-3 polyunsaturated fatty acids with plasma inflammatory biomarkers among the Quebec Cree population

  2014cites this paper
• Tumor necrosis factor alpha -238 G/A and -308 G/A polymorphisms and soluble TNF-α levels in chronic kidney disease: correlation with clinical variables.

  2014cites this paper
• Blockade of p38 mitogen-activated protein kinase pathway ameliorates delayed gastric emptying in streptozotocin-induced diabetic rats.

  2014cites this paper
• Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue.

  2014cites this paper
• LC-MS/MS analysis of plasma polyunsaturated fatty acids in type 2 diabetic patients after insulin analog initiation therapy

  2013cites this paper
• Obesity, immunomodulation and chronic kidney disease.

  2013cites this paper
• Lipoxins, resolvins, protectins, maresins and nitrolipids, and their clinical implications with specific reference to diabetes mellitus and other diseases: part II

  2013cites this paper
• AVALIAÇÃO DA ANEXINA A1, IL-6 E DE VIAS SINALIZADORAS INTRACELULARES NA OBESIDADE E NO DIABETES MELLITUS TIPO 2

  2013cites this paper
• Elevated toll-like receptor 3 inhibits pancreatic β-cell proliferation through G1 phase cell cycle arrest.

  2013cites this paper
• Lipoxins, resolvins, protectins, maresins and nitrolipids, and their clinical implications with specific reference to diabetes mellitus and other diseases: part II

  2013cites this paper
• Lipoxin A Attenuates Obe 4 sity-Induced Adipose Inflammation and Associated Liver and Kidney Disease Graphical

  year unknowninfluential citation